Ak. Salahudeen et al., Anemia and iron target realization in 1998: Clinical management of anemia in 1,639 patients on hemodialysis, ASAIO J, 47(5), 2001, pp. 511-515
Anemia management in hemodialysis patients continues to evolve, and recentl
y, greater emphasis has been placed on the wider use of intravenous iron to
maintain adequate iron levels. This survey provides scarcely available yet
potentially useful information on the clinical treatment of anemia in a la
rge cohort of hemodialysis patients. The erythropoietin and iron administra
tion details and pertinent laboratory measurements from 1,639 patients were
analyzed for the month of December, 1998. A standardized protocol had been
used in that erythropoietin was begun at a total weekly dose of 150 U/kg I
V or 100 U/kg subcutaneously and was then adjusted to maintain a hematocrit
(Hct) of 33-36%. Iron supplements, oral, IV, or both, were administered to
maintain percent transferrin saturation (TSAT) at 20-30% and/or a serum fe
rritin of 100-500 ng/ml. No intravenous iron was administered if the ferrit
in was more than 500 ng/ml. Although 82% of patients were on iron supplemen
tation and, among them, 58% were on IV iron, the percentage of patients wit
h TSAT >20, i.e., bioavailable iron, was only 51%. The serum ferritin was h
igh at 498 +/- 10 ng/ml (mean SEM) and 88% and 10% of patients had serum fe
rritin >100 and >1,000 ng/ml, respectively, suggestive of sequestration of
part of the infused iron. Erythropoietin was administered to 96% of patient
s, 99.5% by IV route. The latter was consistent with the US dialysis popula
tion at large but in variance with DOQI preference for the subcutaneous rou
te. The target Hct range of 33-36 was found in 33%, with a mean Hct of 34.0
+/- 0.12. When the data were reanalyzed by excluding patients who had not
been receiving erythropoietin and had not been on dialysis for at least 3 m
onths, the percentage of patients achieving the target Hct increased to 37%
. Paired analysis of 875 patients present in 1996 and 1998 showed that, alt
hough there was a marked increase in the use of IV iron, the improvement in
anemia was modest, and there was evidence for increased iron accumulation.
In summary, this 1998 survey on the clinical practice of anemia management
in a large hemodialysis population indicates that there is a marked increa
se in need-based IV iron usage that was associated with modest improvement
in anemia and evidence for increased iron storage. A maintenance iron dosin
g protocol with smaller doses of iron, such as 25 mg of iron dextran per he
modialysis, may make bioavailable iron continuously present for erythropoie
sis, yet may reduce the chance for iron catalyzed lipid peroxidation and ti
ssue iron deposition.